Setmelanotide

Phase 2Active

0 views this week 0 watching💤 Quiet

Interest: 36/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Prader-Willi Syndrome

Conditions

Prader-Willi Syndrome, Obesity, Hyperphagia

Trial Timeline

Mar 4, 2025 → Oct 31, 2027

NCT ID

NCT06772597

About Setmelanotide

Setmelanotide is a phase 2 stage product being developed by Rhythm Pharmaceuticals for Prader-Willi Syndrome. The current trial status is active. This product is registered under clinical trial identifier NCT06772597. Target conditions include Prader-Willi Syndrome, Obesity, Hyperphagia.

What happened to similar drugs?

0 of 9 similar drugs in Prader-Willi Syndrome were approved

Approved (0) Terminated (1) Active (8)

🔄somatropin - GH naïve pediatric cohort + somatropin - GH treated cohort + somatropin - adult cohortPfizerPhase 3

🔄CarbetocinAcadia PharmaceuticalsPhase 3

🔄Carbetocin + PlaceboAcadia PharmaceuticalsPhase 3

🔄DCCRSoleno TherapeuticsPhase 3

🔄DCCR + DCCR + Placebo for DCCRSoleno TherapeuticsPhase 3

🔄PitolisantHarmony BiosciencesPhase 3

🔄Pitolisant tabletHarmony BiosciencesPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (8)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06772597	Phase 2	Active	Mar 4, 2025	Oct 31, 2027	Prader-Willi Syndrome
NCT06596135	Phase 3	Recruiting	Oct 21, 2024	Oct 30, 2027	Obesity Associated With Defects in Leptin-melanocortin Pathway
NCT04966741	Phase 3	Completed	Mar 8, 2022	Nov 8, 2024	Bardet-Biedl Syndrome
NCT04725240	Phase 2	Completed	Jun 7, 2021	Jun 28, 2022	Hypothalamic Obesity
NCT04348175	Phase 1	Completed	Jul 9, 2020	Apr 17, 2021	Renal Insufficiency
NCT03651765	Phase 2/3	Completed	Jul 15, 2018	Jan 9, 2025	Obesity Associated With Defects in Leptin-melanocortin Pathway
NCT03262610	Phase 2	Completed	Aug 15, 2017	Jan 31, 2018	Hypertriglyceridemia
NCT03013543	Phase 2	Completed	Feb 10, 2017	Mar 1, 2022	Genetic Obesity

Competing Products

18 competing products in Prader-Willi Syndrome

See all competitors

Product	Company	Stage	Hype Score
Octreotide + Placebo	Novartis	Pre-clinical	18
Norditropin SimpleXx	Novo Nordisk	Pre-clinical	26
somatropin - GH naïve pediatric cohort + somatropin - GH treated cohort + somatropin - adult cohort	Pfizer	Phase 3	40
Setmelanotide + Placebo	Rhythm Pharmaceuticals	Phase 2	32
RGH-706 + Placebo	Richter Gedeon	Phase 2	32
Carbetocin	Acadia Pharmaceuticals	Phase 3	44
Carbetocin + Placebo	Acadia Pharmaceuticals	Phase 3	41
DCCR	Soleno Therapeutics	Phase 3	38
DCCR + DCCR + Placebo for DCCR	Soleno Therapeutics	Phase 3	34
Pitolisant	Harmony Biosciences	Phase 3	41
Pitolisant tablet	Harmony Biosciences	Phase 3	41
Pitolisant oral tablets + Placebo oral tablet	Harmony Biosciences	Phase 2	33
DCCR	Soleno Therapeutics	Phase 3	26
VYKAT XR	Soleno Therapeutics	Pre-clinical	27
DCCR + Placebo for DCCR	Soleno Therapeutics	Phase 3	34
NNZ-2591	Neuren Pharmaceuticals	Phase 2	21
BMB-101 + Placebo	Bright Minds Biosciences	Phase 2	36
ARD-101	Aardvark Therapeutics	Phase 2	25